

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: KUMAR *et al.* Examiner: TBA
Application No.: HEREWITH Group Art Unit: TBA
Filing Date: HEREWITH
For: A BIOAVAILABLE DOSAGE FORM OF LORATADINE




INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231

In accordance with 37 CFR §§ 1.56 and 1.97, attached hereto is Form 1449 and a copy of the reference cited therein.

Respectfully submitted,

KUMAR *et al.*

By: 
Jayadeep R. Deshmukh, Reg. No. 34,507

Dated: June 22, 2001

Ranbaxy Laboratories Limited
600 College Road East, Suite 2100
Princeton, New Jersey 08540
Tel: (609) 720-5608
Fax: (609) 720-9879

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

RLL-178US

Application Number

HEREWITH

Applicant(s)

KUMAR et al.

Filing Date

HEREWITH

Group Art Unit

TBA

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		4,282,233	08/04/1981	VILLANI			

1-886 U.S. PRO
09/888268
05/22/01

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.